Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven L Highfill

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
Current Hematologic Malignancy Reports|July 7, 2019
Overcoming Challenges in Process Development of Cellular TherapiesSteven L Highfill, David F Stroncek
Journal of Translational Medicine|January 16, 2022
Point-of-care cell therapy manufacturing; it's not for everyoneDavid F Stroncek, Robert P T Somerville, Steven L Highfill
International Reviews of Immunology|April 29, 2022
Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapiesHannah W Song, Robert P Somerville, David F Stroncek, et al.
BMC Research Notes|November 19, 2021
Immunomagnetic B cell isolation as a tool to study blood cell subsets and enrich B cell transcriptsAmanda N Henning, Daniel Green, Ryan Baumann, et al.
Molecular Therapy. Methods & Clinical Development|January 9, 2023
Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cellsAlexandra Dreyzin, Sandhya R Panch, Haneen Shalabi, et al.
Molecular Therapy. Methods & Clinical Development|March 8, 2024
Optimization of anti-CD19 CAR T cell production for treatment of patients with chronic lymphocytic leukemiaChristina Amatya, Katherine A Weissler, Vicki Fellowes, et al.
Journal of Translational Medicine|January 26, 2018
Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modulesJianjian Jin, Nikolaos Gkitsas, Vicki S Fellowes, et al.
Science Translational Medicine|May 23, 2014
Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacySteven L Highfill, Yongzhi Cui, Amber J Giles, et al.
Blood|March 13, 2008
Keratinocyte growth factor and androgen blockade work in concert to protect against conditioning regimen-induced thymic epithelial damage and enhance T-cell reconstitution after murine bone marrow transplantationRyan M Kelly, Steven L Highfill, Angela Panoskaltsis-Mortari, et al.
Transfusion|March 14, 2020
Group O plasma as a media supplement for CAR-T cells and other adoptive T-cell therapiesRandin C Nelson, Vicki Fellowes, Ping Jin, et al.
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Current Hematologic Malignancy Reports|July 7, 2019
Overcoming Challenges in Process Development of Cellular TherapiesSteven L Highfill, David F Stroncek
Journal of Translational Medicine|January 16, 2022
Point-of-care cell therapy manufacturing; it's not for everyoneDavid F Stroncek, Robert P T Somerville, Steven L Highfill
International Reviews of Immunology|April 29, 2022
Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapiesHannah W Song, Robert P Somerville, David F Stroncek, et al.
BMC Research Notes|November 19, 2021
Immunomagnetic B cell isolation as a tool to study blood cell subsets and enrich B cell transcriptsAmanda N Henning, Daniel Green, Ryan Baumann, et al.
Molecular Therapy. Methods & Clinical Development|January 9, 2023
Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cellsAlexandra Dreyzin, Sandhya R Panch, Haneen Shalabi, et al.
Molecular Therapy. Methods & Clinical Development|March 8, 2024
Optimization of anti-CD19 CAR T cell production for treatment of patients with chronic lymphocytic leukemiaChristina Amatya, Katherine A Weissler, Vicki Fellowes, et al.
Journal of Translational Medicine|January 26, 2018
Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modulesJianjian Jin, Nikolaos Gkitsas, Vicki S Fellowes, et al.
Science Translational Medicine|May 23, 2014
Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacySteven L Highfill, Yongzhi Cui, Amber J Giles, et al.
Blood|March 13, 2008
Keratinocyte growth factor and androgen blockade work in concert to protect against conditioning regimen-induced thymic epithelial damage and enhance T-cell reconstitution after murine bone marrow transplantationRyan M Kelly, Steven L Highfill, Angela Panoskaltsis-Mortari, et al.
Transfusion|March 14, 2020
Group O plasma as a media supplement for CAR-T cells and other adoptive T-cell therapiesRandin C Nelson, Vicki Fellowes, Ping Jin, et al.
Pageof 6